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Background: Moxifloxacin is a synthetic antibacterial agent belonging to the fluoroquinolone family. The antimicrobial
activity of quinolones against Gram-positive and Gram-negative bacteria is based on their ability to inhibit topoisomerases.
Quinolones are described to have immunomodulatory features in addition to their antimicrobial activities. It was the goal
of this study to examine whether a short term treatment with moxifloxacin modulates the inflammation during a
subsequently induced bacterial infection in an animal model.
Methods: Mice were treated with moxifloxacin or saline for two consecutive days and were subsequently intranasally
infected with viable or heat-inactivated bacterial pathogens (Streptococcus pneumoniae, Pseudomonas aeruginosa) for 6
and 24 hours. Measurements of cytokines in the lungs and plasma were performed. Alveolar cells were determined in
bronchoalveolar lavage fluits.
Results: The inflammation was increased after the inoculation of viable bacteria compared to inactivated bacteria.
Numbers of total immune cells and neutrophils and concentrations of inflammatory mediators (e.g. KC, IL-1β, IL-17A) were
significantly reduced in lungs of moxifloxacin-treated mice infected with inactivated and viable bacterial pathogens as
compared to infected control mice. Plasma concentrations of inflammatory mediators were significantly reduced in
moxifloxacin-treated mice. Immunohistochemistry showed a stronger infiltrate of TNF-α-expressing cells into lungs of
saline-treated mice infected with viable P. aeruginosa as compared to moxifloxacin-treated mice.
Conclusions: These data show that in this pneumonia model moxifloxacin has anti-inflammatory properties beyond its
antibacterial activity.
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Respiratory tract diseases, such as pneumonia, cystic fi-
brosis (CF), and chronic obstructive pulmonary disease
(COPD), are worldwide a leading cause of mortality [1].
Acute and chronic inflammations leading to destruction
of lung tissue are characteristic hallmarks of these dis-
eases. For example, in severe pneumonia the infecting
pathogens and the inflammatory response of the host
cause a breach of epithelial and endothelial barriers
[2,3]. As a pathophysiological consequence, bacteria,
components of bacteria (e.g. LPS, lipoproteins), and* Correspondence: christoph.beisswenger@uks.eu
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article, unless otherwise stated.inflammatory mediators translocate from epithelial sur-
faces into subepithelial compartments and into the
bloodstream. In subepithelial compartments, bacteria
and components of bacteria are recognized by immune
cells. Activated immune cells further contribute to ex-
cessive inflammation by releasing inflammatory media-
tors and directing additional effector cells from the
bloodstream into the parenchyma of the lung [4]. Thus,
formation of edema and impaired pulmonary gas ex-
change are a hallmark of severe pneumonia [2,3]. Acute
and chronic inflammation and infection of the lung also
contribute to tissue destruction and loss of lung func-
tion in COPD and CF [1,5]. Bacterial and viral infections
are associated with exacerbations of COPD [1,6]. In CF,
ongoing inflammation and activation of immunentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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aeruginosa [7].
Moxifloxacin is a synthetic antibacterial agent belonging
to the fluoroquinolone family. Moxifloxacin is well estab-
lished in the treatment of patients suffering from pneumo-
nia [8] or acute exacerbation of COPD [9]. The minimum
inhibitory concentrations (MICs) for moxifloxacin have
been shown to be between 0.8 to 2 mg/l for P. aeruginosa
(e.g. strain PAO1) and 0.06 to 0.5 mg/l for S. pneumoniae
[10-13]. The antimicrobial activities of fluoroquinolones
such as moxifloxacin are based on their ability to inhibit
topoisomerases (e.g. DNA gyrase and topoisomerase IV).
There is strong evidence that fluoroquinolones addition-
ally exhibit immunomodulatory functions during inflam-
mation and microbial infection besides their bactericidal
activities [8]. In vitro studies showed that clinically rele-
vant concentrations of moxifloxacin inhibit the synthesis
of inflammatory mediators (e.g. IL-1, TNF-α, IL-6, IL-8) in
human peripheral blood mononuclear cells and in the
monocytic cell line THP-1 stimulated with LPS, LTA,
heat-inactivated bacteria, and Aspergillus fumigatus. This
is likely due to the inhibition of NF-κB- and MAP kinase-
dependent signaling pathways [14-16]. In vitro studies fur-
ther revealed that moxifloxacin inhibits the activation of
MAP kinase and NF-kB signaling cascades, the synthesis
of nitric oxide, and the expression of the chemokines IL-6
and IL-8 in human respiratory epithelial cell lines stimu-
lated with inflammatory cytokines [17,18]. To date, it is
not sufficiently understood how fluoroquinolones modu-
late inflammation and particularly the activation of cellu-
lar signaling molecules such as NF-κB- or MAP kinases.
However, it has been shown that fluoroquinolones affect
phosphodiesterases and intracellular cAMP levels [19,20].
In addition, it has also been suggested that the immuno-
modulatory effects of fluoroquinolones are due to the in-
hibition of topoisomerases, which leads to a stress
response in eukaryotic cells [8,19,21].
It was the goal of this study to gain insight into the
immunomodulatory features of moxifloxacin during
murine pneumonia. To study whether moxifloxacin
modulates the inflammatory response of the host mice
were treated with moxifloxacin before infection of the
lung with viable or heat-inactivated bacterial pathogens.
Infection with heat-inactivated bacteria allowed examin-
ing the effects of moxifloxacin treatment on the inflam-
matory response of the host without being affected by
the impact of moxifloxacin on the viability of the bac-
teria. To demonstrate whether the immunomodulatory
features of moxifloxacin depend on the infecting bacter-
ial species we chose to infect mice with distantly related
Gram-negative and Gram-positive bacterial species
(S. pneumoniae, P. aeruginosa) which are known to have
different susceptibility to moxifloxacin. The results fur-
ther demonstrate whether a bacterial stimulation usinginactivated bacteria differs in comparison to an infec-
tion caused by viable bacteria.Methods
Mouse experiments
P. aeruginosa strain PAO1 was grown overnight at 37°C
on LB agar plates. Bacterial cells were taken from the
plate, resuspended in LB medium, and incubated for 2-4
hours at 37°C and 150 rpm. A type 6A clinical isolate of S.
pneumoniae was cultured as described before [22]. After
washing with PBS, bacteria were adjusted to OD600 = 1
and heat-inactivated for 10 min at 95°C or used directly
for infection. Mice (C57BL/6N) were maintained under a
pathogen-free condition. All animal experiments were ap-
proved by the Landesamt für Soziales, Gesundheit und
Verbraucherschutz of the State of Saarland following the
national guidelines for animal treatment. To examine the
effect of moxifloxacin on the inflammatory response of
the host during bacterial pneumonia mice were injected i.
p. with 100 mg/kg moxifloxacin twice a day for two con-
secutive days. Control mice received saline. Two hours
after the final moxifloxacin injection, moxifloxacin-treated
and control animals were infected with bacteria [23]. Mice
were slightly anesthetized by i.p. injection of 2.6 mg
of ketaminhydrochloride (Ketanest; Pfizer, Germany) and
0.18 mg of xylazinhydrochloride (Rompun; Bayer, Germany)
per mouse and infected intranasally with heat-inactivated
(low dose: 1 × 106 to 5 × 106 CFU, high dose 1 × 107 to 5 ×
107 CFU) and viable (1 × 107 to 5 × 107) P. aeruginosa and
with heat-inactivated and viable S. pneumoniae (5 × 106 to
1 × 107) or with PBS alone as control. At least five mice per
group were infected with viable or inactivated bacteria or
treated with PBS as control. Six or 24 hours after the bacter-
ial infection, mice were euthanized, the tracheae were can-
nulated and a bronchoalveolar lavage (BAL) was performed
with 1 ml of PBS flushed three times into the lungs. Lungs
were removed for immunohistochemistry. BAL fluids were
centrifuged at 4°C to obtain BAL cells and cell-free superna-
tants. Alveolar cells were suspended in 1 ml of PBS. Total
cell numbers were determined and cytospins were prepared.
Macrophages, neutrophils, lymphocytes, and eosinophils
were differentiated by light microscopy. Blood was collected
by cardiac puncture into EDTA (15 μl, 0.8 M) containing 1
ml syringes and plasma was removed after centrifugation.
Plasma and BAL fluids were kept at -80°C until use.Determination of cytokine concentrations
Concentrations of the inflammatory cytokines KC and
IL-1β were assessed by enzyme-linked immunosorbent
assay (ELISA) using a Tecan Ultra 384 ELISA reader and
the software Magellan (Tecan, Germany). All ELISA kits
were purchased from R&D Systems (UK) and used as
instructed by the manufacturer. IL-17A and IL-10 were
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RNA isolation and realtime RT-PCR
Total RNA from lungs was isolated using TRIzol reagents
(Life Technologies, Germany) according to the manufactur-
er's manual. 1 μg of total RNA was reversely transcribed to
cDNA using the RevertAid First Strand cDNA Synthesis
Kit (Thermo Scientific, Germany) according to the manu-
facturer's manual. qRT-PCR was performed with a reaction
mix including the SensiMix SYBR & Fluorescein Kit
(Bioline, Germany), using the iCycler (Bio-Rad Laboratories,
Germany) with a 2-step protocol (15 sec at 95°C/45 sec at
60°C). Specificity of amplification was controlled by melt
curve analysis and gelelectrophoresis. RT-PCR results were
analysed with the ΔΔCT method [24], using GAPDH as an
internal standard to normalize mRNA amounts.
Immunohistochemistry
Lungs of mice were embedded in paraffin and immuno-
histochemistry was performed as described earlier [25].
TNF-α was detected with primary antibodies (Abcam,
UK) diluted 1:100 in TBS (Tris-buffered saline). A bio-
tinylated anti-rabbit secondary antibody was added
(DAKO, Denmark), followed by avidin-horseradish per-
oxidase reagent (EnVision System (AEC), DAKO,
Denmark). Imaging was performed using the software
Cell Sense Dimension (Olympus, Germany). TNF-α
staining was quantified (% area) using ImageJ software.
Statistical analysis
Values are displayed as mean ± SEM. Comparisons
between groups were analyzed by ANOVA (Newman-
Keuls multiple comparison test). Results were considered
statistically significant for p < 0.05. All statistical tests were
performed using the software Prism (GraphPad Software,
San Diego, CA, USA).
Results
Moxifloxacin treatment affects the influx of immune cells
into lungs during bacterial pneumonia
Moxifloxacin treatment resulted in an increased clear-
ance of P. aeruginosa and S. pneumoniae in the lungs of
mice infected with viable bacteria indicating a bacteri-
cidal activity of moxifloxacin in our pneumonia model
against both bacterial species. No viable bacteria were
detected in BAL fluids of moxifloxacin-treated mice in-
fected with 5 × 106 CFU of S. pneumoniae 24 hours post
infection, whereas 7 × 103 (±3 × 103) CFU of viable S.
pneumoniae were determined in BAL fluids of saline-
treated control mice. In mice infected with 107 CFU of
P. aeruginosa for 6 hours, 4 × 105 (±2 × 105) CFU were
detected in BAL fluids of saline-treated control mice and9 × 102 (±1.3 × 103) CFU in BAL fluids of moxifloxacin-
treated mice.
Moxifloxacin treatment did not affect the levels of
total immune cells (Figure 1) and neutrophils (Figure 2)
in the lungs of mice in the absence of bacterial infection.
Infection with heat-inactivated and viable bacteria re-
sulted in a neutrophil-dominated inflammatory response
in the lung. The infection with heat-inactivated and vi-
able P. aeruginosa and S. pneumoniae led to enhanced
numbers of total immune cells (Figure 1) and neutro-
phils (Figure 2) in BAL fluids 6 and 24 hours post infec-
tion as compared to non-infected control groups.
Furthermore, in the case of S. pneumoniae, viable bac-
teria induced a significantly enhanced influx of total im-
mune cells (Figure 1E) and neutrophils (Figure 2E) into
lungs as compared to heat-inactivated S. pneumoniae.
Interestingly, treatment with moxifloxacin affected the
levels of total immune cells and neutrophils in the lungs
of mice infected with viable and heat-inactivated bac-
teria. Treatment with moxifloxacin, as compared to
saline, resulted in significantly reduced levels of total im-
mune cells (Figure 1A to C) and neutrophils (Figure 2A
to C) in BAL fluids of mice infected with a low dose or a
high dose of heat-inactivated P. aeruginosa or with vi-
able S. pneumoniae (Figures 1E and 2E). There was no
difference in the numbers of total immune cells in BAL
fluids between moxifloxacin- and saline-treated mice in-
fected with viable P. aeruginosa (Figures 1D and 2D).
Levels of macrophages and lymphocytes in BAL fluids
were not affected by treatment with moxifloxacin (data
not shown).
These data suggest that moxifloxacin attenuates the
inflammatory response in the lung during murine pneu-
monia partly independent of its bactericidal activity.
Expression of inflammatory cytokines in lungs of
moxifloxacin-treated mice
Next, we examined whether a treatment with moxifloxa-
cin modulates the expression of inflammatory mediators
in the lung upon bacterial infection. Moxifloxacin per se
did not affect the levels of the inflammatory mediators
IL-1β (Figure 3), KC (the functional homologue of IL-8
in mice, Figure 4) and IL-17A (Figure 5) in the lungs of
mice in the absence of bacterial infection. Concentra-
tions of IL-1β, KC and IL-17A were significantly in-
creased in lungs of mice infected with heat-inactivated
and viable P. aeruginosa and S. pneumoniae as compared
to the concentrations in lungs of non-infected control
mice. Furthermore, infection with viable bacteria in-
duced significantly enhanced expression of these cyto-
kines as compared to infection with heat-inactivated
bacteria. Treatment with moxifloxacin resulted in a re-
duced expression of IL-1β, KC and IL-17A in lungs of
mice infected with viable bacteria, whereas the levels of
Figure 1 Moxifloxacin treatment results in a reduced influx of immune cells into the lung during bacterial pneumonia. BAL fluids of
moxifloxacin- and saline-treated mice were collected 6 or 24 h post intranasal infection with heat-inactivated P. aeruginosa (A/B/C), viable
P. aeruginosa (D), and heat-inactivated or viable S. pneumoniae (E). Total cell numbers were determined. Data are shown as mean ± SEM. Bars
indicate significant differences of *p < 0.05, **p < 0.01, and ***p < 0.001, (n≥ 5 for each group).
Figure 2 Moxifloxacin treatment results in a reduced influx of neutrophils into the lung during bacterial pneumonia. BAL fluids of
moxifloxacin- and saline-treated mice were collected 6 or 24 h post intranasal infection with heat-inactivated P. aeruginosa (A/B/C), viable
P. aeruginosa (D), and heat-inactivated or viable S. pneumoniae (E). Total numbers of neutrophils were determined. Data are shown as mean ± SEM.
Bars indicate significant differences of *p < 0.05, **p < 0.01, and ***p < 0.001, (n≥ 5 for each group).
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Figure 3 Effect of moxifloxacin on IL-1β concentrations in lungs of infected mice. IL-1β concentrations were measured in lungs of
moxifloxacin- and saline-treated mice 6 or 24 h post intranasal infection with heat-inactivated P. aeruginosa (A/B/C), viable P. aeruginosa (D), and
heat-inactivated or viable S. pneumoniae (E). Data are shown as mean ± SEM. Bars indicate significant differences of *p < 0.05, **p < 0.01, and
***p < 0.001 (n≥ 5 for each group).
Figure 4 Effect of moxifloxacin on KC concentrations in lungs of infected mice. KC concentrations were measured in lungs of moxifloxacin- and
saline-treated mice 6 or 24 h post intranasal infection with heat-inactivated P. aeruginosa (A/B/C), viable P. aeruginosa (D), and heat-inactivated or
viable S. pneumoniae (E). Data are shown as mean ± SEM. Bars indicate significant differences of *p < 0.05, **p < 0.01, and ***p < 0.001 (n≥ 5 for
each group).
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Figure 5 Effect of moxifloxacin on IL-17A concentrations in lungs of infected mice. IL-17A concentrations were measured in BAL fluids of
moxifloxacin- and saline-treated mice 6 or 24 h post intranasal infection with heat-inactivated P. aeruginosa (A/B) or viable P. aeruginosa (C). Data
are shown as mean ± SEM. Bars indicate significant differences of *p < 0.05, **p < 0.01, and ***p < 0.001 (n≥ 5 for each group).
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inactivated bacteria were only partially affected by moxi-
floxacin as compared to saline. IL-β concentrations were
reduced in lung homogenates of moxifloxacin-treated
mice infected for 6 hours with heat-inactivated P. aerugi-
nosa (Figure 3A) and viable P. aeruginosa (Figure 3D)
and in lung homogenates of mice infected with viable S.
pneumoniae for 24 hours (Figure 3E). IL-1β could only
be detected in BAL fluids from saline-treated mice in-
fected with viable P. aeruginosa (1203 ng/ml ± 126),
whereas IL-1β concentrations were below the detection
limit in BAL fluids of moxifloxacin-treated mice infected
with viable P. aeruginosa and in BAL fluids of mice in-
fected with heat-inactivated bacteria (data not shown).
Treatment with moxifloxacin resulted in significantly re-
duced concentrations of KC in lung homogenates of
mice infected with viable P. aeruginosa (Figure 4D) and
S. pneumonia (Figure 4E) as compared to saline-treated
mice. KC concentrations were also significantly (p <
0.001) reduced in BAL fluids from moxifloxacin-treated
mice infected with viable P. aeruginosa (5.4 × 104 ng/ml ±
1533) as compared to infected saline-treated mice
(2.1 × 104 ng/ml ± 7507). IL-17A concentrations were
significantly reduced in BAL fluids of moxifloxacin-
treated mice infected with a high dose of heat-
inactivated for 24 hours (Figure 5B) and viable P.
aeruginosa (Figure 5C) as compared to the correspond-
ing saline-treated mice. IL-17A was below the detection
limit in mice treated with a low dose of inactivated P.
aeruginosa for 6 hours (data not shown). Levels of the
anti-inflammatory cytokine IL-10 in BAL fluids were
below the detection limit (10 pg/ml) in infected and
non-infected mice (data not shown). Relative mRNA ex-
pression levels of inflammatory mediators were deter-
mined in whole lungs of mice infected with inactivated
and viable P. aeruginosa for 6 hours. In case of infection
with inactivated P. aeruginosa, expression of KC
was slightly enhanced in lungs of saline-treated micecompared to moxifloxacin-treated mice (Figure 6A). In-
fection with viable P. aeruginosa resulted in significantly
increased expression levels of KC in lungs of saline-
treated mice as compared to moxifloxacin-treated mice
(Figure 6B). The expression of IL-β was significantly in-
creased in moxifloxacin-treated mice infected with inac-
tivated and viable P. aeruginosa (Figure 6C and D). No
significantly increased levels of expression could be de-
termined for IL-17 6 hours post infection by qRT-PCR
(data not shown). In addition, infection with viable P.
aeruginosa for 6 hours resulted in an infiltrate of TNF-
α-expressing cells into lungs. Figure 7 shows representa-
tive hematoxylin/eosin and TNF-α staining of lung
sections from areas with strong and moderate cell infil-
trates. The infiltrate of TNF-α-expressing cells into
lungs of saline-treated mice was significantly increased
as compared to moxifloxacin-treated mice (Figure 7C).
Concentrations of KC in blood of mice treated with
moxifloxacin
To determine whether moxifloxacin treatment affects
cytokine levels in blood during bacterial pneumonia KC
concentrations were measured in blood plasma. Treat-
ment with moxifloxacin per se did not affect concentra-
tions of KC in plasma in the absence of bacterial
infection (Figure 8). KC concentrations were significantly
increased in plasma of mice infected with heat-
inactivated (Figure 8A and B) and viable (Figure 8C
and D) bacteria as compared to non-infected control
mice. Infection with viable P. aeruginosa and S. pneumo-
niae resulted in significantly enhanced concentrations of
KC as compared to infection with heat-inactivated bac-
teria. Furthermore, KC concentrations were significantly
reduced in plasma of moxifloxacin-treated mice infected
with heat-inactivated P. aeruginosa (Figure 8A and B),
live P. aeruginosa (Figure 8C) and live S. pneumoniae
(Figure 8D) as compared to the concentrations in the
plasma of the corresponding saline-treated control mice.
Figure 6 Moxifloxacin affects the expression of inflammatory cytokines in lungs. The relative expression of KC (A/B) and IL-1β (C/D) was
measured in whole lungs of moxifloxacin- and saline-treated mice 6 post intranasal infection with heat-inactivated P. aeruginosa (A/C) or viable
P. aeruginosa (B/D) via qRT-PCR. Data are shown as mean ± SEM. Bars indicate significant differences of *p < 0.05, **p < 0.01, and ***p < 0.001
(n≥ 5 for each group).
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dose of heat-inactivated P. aeruginosa for 24 hours were
not significantly increased in saline or moxifloxacin-
treated mice (data not shown). Thus, treatment with
moxifloxacin results in reduced levels of inflammatory cy-
tokines in the blood stream during murine pneumonia.Discussion
This study focused on the immunomodulatory functions
of the fluoroquinolone moxifloxacin. The principle findingis that moxifloxacin attenuates local and systemic inflam-
mation during bacterial pneumonia in mice and that the
anti-inflammatory properties of moxifloxacin depend on
both its bactericidal and non-bactericidal activities.
Moxifloxacin is well established in the clinical treatment
of patients suffering from community-acquired pneumonia
[26] and acute exacerbation of COPD [21]. In addition, an
immunomodulatory effect of moxifloxacin is assumed in
clinical situations [8]. Kazama and colleagues, for instance,
reported an interesting case of a woman with a dual lung
infection caused byMycoplasma pneumoniae and Bordetella
Figure 7 Moxifloxacin treatment results in a reduced infiltrate of TNF-α-expressing cells. Moxifloxacin- and saline-treated mice were
infected intranasally with viable P. aeruginosa for 6 h. (A) Hematoxylin and eosin staining. (B) TNF-α is shown by immunohistochemistry. Scale bar
represents 200 μm. Samples from three different animals per group are shown. (C) Quantification of TNF-α staining in 4 slides per mouse. Bar
indicates significant difference of p < 0.05.
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apy with three different antibiotics in series. Only the subse-
quent treatment with moxifloxacin led to a dramatic clinical
improvement and the disappearance of the migratory pul-
monary infiltrates. The authors postulated a immunomodu-
latory role of moxifloxacin suppressing the lymphocyte
activity [27]. Furthermore, several in vitro studies showed
that moxifloxacin attenuates the inflammatory response in
diverse cell types (e.g. monocytes, respiratory epithelial cells)
induced by microbial stimuli and inflammatory mediators
by inhibiting the activation of MAP kinases and NF-kB
[14-18,28]. Moxifloxacin reduced the cytokine-induced acti-
vation of the transcription factor NF-κB and MAP kinases
and the synthesis of nitric oxide in the alveolar epithelial cell
line A549 [17] and the TNF-α-induced NF-κB- and MAP-
kinase-dependent expression of inflammatory mediators
(IL-6, IL-8) in cystic fibrosis epithelial cells [18]. Moxifloxa-
cin also inhibited the activation of MAP kinases and NF-κB
and the release of inflammatory mediators in human mono-
cytes in response to bacterial stimuli [14-16].
To study whether moxifloxacin reduces the inflamma-
tory response of the host to microbial pathogens as seen
in the in vitro studies mentioned above we treated mice
with moxifloxacin prior to infection with viable or heat-
inactivated bacterial pathogens. In line with the in vitro
studies, our murine pneumonia model showed that sys-
temic treatment with moxifloxacin results in an attenu-
ated inflammatory response with reduced levels of
pro-inflammatory mediators and neutrophils in the
lungs of mice infected with viable and heat-inactivated
S. pneumoniae and P. aeruginosa. Even though the in-
flammation was more accentuated after the inoculation
of viable bacteria than of inactivated bacteria and moxi-
floxacin was more efficient in suppressing the strong
inflammation induced by viable bacteria, infection with
inactivated bacteria demonstrated that the anti-inflammatory properties of moxifloxacin partly depend
on its non-bactericidal activities. A protective function
of moxifloxacin apart from its bactericidal activity could
also be determined in a murine pneumonia model with
Candida albicans in which treatment with moxifloxacin
resulted in reduced levels of inflammatory mediators in
the lung during the course of infection [28]. In that re-
port, the beneficial reduction of inflammation in the
Candida-albicans-induced pneumonia model could not
be explained by an antifungal effect of moxifloxacin.
This further supports an anti-inflammatory potency
of moxifloxacin completely separate from its antimicro-
bial effect. As moxifloxacin modulated the inflammatory
response to distantly related Gram-negative and
Gram-positive bacteria with different susceptibility to
moxifloxacin and to fungal species, treatment with
moxifloxacin may be beneficial for patients with
infection-related lung diseases by reducing the inflam-
matory burden of the lung independent of the infecting
pathogen and its susceptibility to the drug.
It is difficult to deduce the specific cell types affected
by moxifloxacin from this in vivo study. It seems to be
reasonable that moxifloxacin directly effects the activa-
tion of immune cells (e.g. alveolar macrophages) by bac-
terial pathogens in the infected lungs as observed in the
mentioned in vitro studies, since IL-17A is expressed by
immune cells and not by epithelial cells [29] and macro-
phages are a main source of IL-1β during acute infection
of the lung [25]. The finding that treatment with moxi-
floxacin resulted in reduced IL-1β protein concentra-
tions but in increased mRNA transcription in the lungs
of mice infected with viable bacteria whereas KC tran-
scription and protein concentrations were reduced in
lungs of moxifloxacin-treated mice suggests that moxi-
floxacin modulates inflammation at different levels.
Additional studies are needed to examine whether
Figure 8 Levels of KC are reduced in blood of mice treated with moxifloxacin. KC concentrations were measured in plasma of moxifloxacin
and saline-treated mice infected intranasally with heat-inactivated P. aeruginosa (A/B), viable P. aeruginosa (C), and heat-inactivated or viable S.
pneumoniae (D) for 6 or 24 h. Bars indicate significant differences of *p < 0.05, **p < 0.01, and ***p < 0.001 (n≥ 5 for each group).
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inflammasome that mediates the activation and release
of IL-1β and whether moxifloxacin-treatment differentially
affects signaling pathways required for mRNA-transcription
and stabilization of specific cytokins. Furthermore, the acti-
vation of respiratory epithelial cells also may be modulated
by moxifloxacin as epithelial cells are a source of KC dur-
ing bacterial pneumonia [25].
Moreover, viability of the bacterial pathogens per se
also affected the inflammatory response of the host. In-
fection with viable bacteria resulted in absolute levels of
pro-inflammatory mediators in the lungs and in plasma
of mice that were approximately one magnitude higher
as compared to infection with heat-inactivated bacteria,
even though infection with heat-inactivated P. aerugi-
nosa resulted in a robust influx of total immune cells
and neutrophils into the lungs. In addition, moxifloxacinimpacted viability of P. aeruginosa and S. pneumoniae.
Fewer bacteria could be cultured from lungs of mice
treated with moxifloxacin and infected with viable bac-
teria as compared to lungs of mice treated with saline.
The bactericidal activity of moxifloxacin correlated with
the inflammatory response of the host since treatment
with moxifloxacin, as compared to saline, resulted in re-
duced levels of inflammatory mediators in lungs and in
plasma of mice infected with viable P. aeruginosa and S.
pneumoniae and in a reduced influx of immune cells
into lungs of mice infected with S. pneumoniae. These
results indicate that the viability of bacteria determines
the inflammatory response of the host and are in line
with a study of Sander et al. [30] showing that the im-
mune system can distinguish viable from dead microor-
ganisms by sensing prokaryotic viability-associated
patterns resulting in differential release of inflammatory
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IL-1β. In line with this study, we found that viability of
bacteria does not affect the expression of IL-1β at a tran-
scriptional level. However, inactivation of bacteria re-
sulted in significantly reduced protein levels of IL-β in
lungs of infected mice. Thus, moxifloxacin seems to
modulate inflammation during bacterial pneumonia by
reducing the amount of viability-associated patterns and
via mechanisms independent of its bactericidal activity.
In conclusion, we show that moxifloxacin reduces the
“hyper-inflammation” during murine pneumonia. Pre-
treatment with moxifloxacin attenuates local and sys-
temic inflammation during bacterial pneumonia in mice.
The non-bactericidal properties may be beneficial for pa-
tients with infection-related lung diseases.
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